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ABSTRACT Tolevamer, (GT160-246), is a sodium salt of styrene sulfonate polymer that is under development for the
treatment of diarrhea caused by infection with Clostridium difﬁcile. Pulsed ultraﬁltration binding experiments in phosphate buffer
containing 0.15 M Na1 provide per polymer chain dissociation constants of 133 nM and 8.7 mM for the binding of tolevamer to
C. difﬁcile toxins A and B, respectively. At 0.05 M Na1, the binding of toxin A to tolevamer is irreversible, whereas the
dissociation constant to toxin B under these conditions is 120 nM. Binding constants obtained from ﬂuorescence polarization
data for toxin A binding to tolevamer at 0.15 M Na1 agree substantially with those obtained by pulsed ultraﬁltration. The binding
activity of tolevamer reported here correlates well with previously reported results for the inhibition of the biological activity of C.
difﬁcile toxins A and B. From the ﬂuorescence polarization data, it is estimated that one toxin A molecule interacts with between
600 to 1000 monomer units on tolevamer at 0.15 M Na1. Thus, the data suggest a very large interaction surface between
polymer and toxin A.
INTRODUCTION
Clostridium difﬁcile infection is the major identiﬁed cause of
antibiotic-associated diarrhea in hospitals. Under ordinary
conditions, the presence of normal intestinal ﬂora inhibits the
growth of C. difﬁcile. However, after antibiotic treatment, C.
difﬁcile can proliferate in the lower intestinal tract. C. difﬁcile
infection results in symptoms including profuse diarrhea and
abdominal pain (Pothoulakis and LaMont, 1993; Kelly and
LaMont, 1998). In severe cases, pseudomembranous colitis
and toxic megacolon may occur (Pothoulakis and LaMont,
1993; Kelly and LaMont, 1998; Sheth and LaMont, 1998).
C. difﬁcile infection is typically treated with one of two
antibiotics, metronidazole or vancomycin. Relapse of
disease after such antibiotic treatment occurs in 5–20% of
patients, most likely because such antibiotics continue to
suppress not only C. difﬁcile growth, but also the growth of
normal competitive intestinal ﬂora.
The symptoms of C. difﬁcile infection are mediated by two
high molecular mass protein toxins produced by this bacte-
rium, toxins A and B. Toxin A is thought to play the primary
role in antibiotic-associated diarrhea, though toxin B appears
to be signiﬁcant as well (Lyerly et al., 1988; Riegler et al.,
1995; Limaye et al., 2000).
An attractive approach to the treatment of C. difﬁcile
infection would involve binding and neutralizing C. difﬁcile
toxins without disrupting the reestablishment of normal
bacterial growth. Cholestyramine, a cationic resin that has
been used clinically as a bile acid sequestrant, binds C.
difﬁcile toxins in vitro (Taylor and Bartlett, 1980), and has
been tested in humans as a treatment for C. difﬁcile colitis.
However, the activity shown by this resin was modest, and
it is not recommended for the treatment of severe colitis
(Burbige and Milligan, 1975; George et al., 1980; Tedesco,
1982). In previous work, we have shown that modest doses
of tolevamer, a high molecular mass nonantimicrobial
polymer, neutralizes both toxin A and toxin B mediated
inhibition of protein synthesis in Vero cells, and substantially
decreases toxin A mediated ﬂuid accumulation and perme-
ability in a rat ileal loop model (Kurtz et al., 2001). Most
signiﬁcantly, tolevamer substantially reduces the mortality
of C. difﬁcile-infected hamsters (Kurtz et al., 2001). In the
work reported here we demonstrate that tolevamer binds
both toxins A and B with signiﬁcant afﬁnity, and that the
binding afﬁnities we have determined correlate well with the
ability of tolevamer to neutralize the activities of these
toxins. We demonstrate further that the binding of toxins A
and B is not a general property of polyanions, since poly(2-
acrylamido-2-methyl-1-propanesulfonate) (AMPS), a high
molecular mass polyanion of similar charge density to
tolevamer, does not bind either toxin to any measurable
extent.
MATERIALS AND METHODS
Materials
Chemically, tolevamer is a high molecular mass sodium salt of polystyrene
sulfonate, prepared by Genzyme Corporation (Cambridge, MA). For the
ﬂuorescence polarization measurements, ﬂuorescein-labeled tolevamer was
synthesized at Genzyme by copolymerization of styrene sulfonate with
FITC-labeled 4-aminostyrene. As estimated by UV absorbance, the polymer
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was labeled to;1 mol %. AMPS was purchased from Aldrich (Milwaukee,
WI) and puriﬁed by dialysis. The molecular masses of tolevamer and AMPS,
measured by size-exclusion chromatography (SEC) with UV detection, were
estimated to be 600 kDa and 200 kDa, respectively. 10x phosphate buffered
saline buffer (PBS), pH ¼ 7.0, was obtained from GIBCO (Carlsbad, CA),
and diluted with Millipore (Billerica, MA) ﬁltered water to give 50 mM
sodium ion (low salt buffer) or 150 mM sodium ion (physiological buffer).
C. difﬁcile toxins were obtained from TECHLAB (Blacksburg, VA). The
concentration of toxin A was 2 mg/ml and the concentration of toxin B
varied between 0.2 to 0.44 mg/ml. The molecular masses of toxins A and B
are 308 and 270 kDa, respectively.
Pulsed ultraﬁltration methods
The pulsed ultraﬁltration (PUF) cell used in this study followed the design
of Woodbury and Venton (Chen et al., 1998; Woodbury and Venton,
1998,1999). The cell volume was 1 ml. The Millipore ultraﬁlter membranes
used in the cell had a nominal molecular mass cutoff of 500 kDa. The cell
was kept at a constant temperature of 25C by immersing in a constant
temperature water bath. AWaters 2690 Separation pump was used to control
the sample injection and buffer ﬂow rate (0.2 ml/min). A Waters 996
Photodiode Array Detector was used for detection at 280 nm and data were
collected in digital format. Before the start of the experiment, toxin samples
were stored at 5C.
PUF experiments consisted of four steps, and took ;6 h. Each new
membrane was ﬁrst ﬂushed through with buffer for 2–3 h or until a stable
baseline was achieved. Protein ligand was injected and monitored for 1 h in
the absence of polymer. Then, polymer was injected and washed with buffer
for;2 h. Finally, the same amount of protein ligand was again injected and
monitored for 1 h to assess polymer-protein binding.
The mathematical analysis of the PUF method follows closely that
described by Chen et al. (1998). Brieﬂy, in the absence of ligand binding, the
ﬂow curve after the injection of a short pulse of ligand into the cell reﬂects
the dilution of the ligand by the continuous ﬂow of buffer through the
system:
LfðtÞ ¼ L0 expðFt=VcÞ; (1)
where Lf(t) is the concentration of ligand exiting the cell, as monitored by
UV absorption, F is the ﬂow rate, in ml/min, t is the time in minutes, and Vc
is the physical volume of the cell, in milliters. L0 ¼ N0/Vc, where N0 is the
total moles of ligand injected into the cell. For an inﬁnitely narrow pulse, L0
would thus be the initial total concentration of ligand in the cell immediately
after injection of the pulse of ligand. In our analysis, we determined Vc by
ﬁtting the blank ﬂow curve to Eq. 1. The values thus obtained agreed to
within 10% to the physical volume of the cell, as estimated by injecting
liquid into the cell.
In the presence of polymer in the cell, Nb, the number of moles of bound
ligand at any time is given by the equation of mass balance:
NbðtÞ ¼ N0  NoutðtÞ  NfðtÞ; (2)
where Nout(t) is the number of moles of ligand that have exited the cell, and
Nf(t) is the number of moles of free ligand remaining in the cell. Nout(t) can
be obtained by integrating from time t toN:
NoutðtÞ ¼ N0 
Z N
t
LfðtÞFdt: (3)
Substituting this expression into (2) and simplifying, we obtain:
NbðtÞ ¼
Z N
t
LfðtÞFdt  LfðtÞVc: (4)
Hence, we can obtain Nb(t) at any point in the ﬂow curve by integrating
over time, from some convenient starting point t. A better method, which we
used in our analysis, is the constant concentration method (Chen et al.,
1998). This method corrects for the effects of nonspeciﬁc binding, and does
not require explicit knowledge of Vc. According to this method, the
difference at constant concentration Lf(t) is taken between the area under the
curve for the sample containing polymer and the blank sample containing no
polymer. This difference deﬁnes Nb(t):
NbðtÞ ¼
Z N
t
LfðtÞF dt 
Z N
tb
L
b
f ðtÞF dt; (5)
where the ﬁrst integral reﬂects integration of the sample from the time t at
which the free concentration of ligand exiting the sample cell is equal to Lf,
and the second integral reﬂects integration from the time tb, where the free
concentration of ligand exiting the blank cell is equal to the same value Lf(t).
Data processing was performed by ﬁtting the free ligand ﬂow curve to
extract the ﬂow cell volume, and calculating the free and bound ligand
concentration from the ﬂow curves. The ﬁtting of the extracted bound-free
ligand curve to obtain the binding parameters was performed using the
program SigmaPlot (SPSS Inc.).
Fluorescence polarization methods
Fluorescence polarization provides another method for determining binding
parameters (Jameson and Sawyer, 1995). Fluorescence polarization
measurements were performed in a 96-well format (LJL Analyst) using an
excitation ﬁlter centered at 485 nm, an emission ﬁlter centered at 530 nm,
and a dichroic mirror with a short wavelength cutoff of 505 nm.
Toxin dilutions were made directly in the 96-well plates, for each con-
stant concentration of ﬂuorescein-labeled tolevamer (FL-tolevamer) moni-
tored. Duplicate data points were obtained for each concentration of toxin
and polymer. The variation in these duplicate points provided the reported
estimates of the standard deviation. For each sample, the background ﬂuo-
rescence was subtracted using blanks containing the same concentration of
toxin, but no added polymer. Background subtracted intensities of polarized
light were monitored, and the polarization in mP was determined from the
equation
P ¼ 1000  Ik  I?
Ik1 I?
 
; (6)
where Ik is the intensity of light parallel to the direction of the incident light,
and I? is the intensity of light perpendicular to the polarization of the
incident light. Deﬁned in this manner, the polarization in mP has a theoretical
range from 0 for complete depolarization to 500 for a completely rigid
system.
Upon binding to toxin, the polarization of FL-tolevamer increases as the
rotational mobility of the ﬂuorescein probe decreases. Using the method of
isoparametric analysis (Chatelier and Sawyer, 1987; Winzor and Sawyer,
1995), we have determined binding curves for the interaction. In this
method, the toxin concentration is varied at constant polymer concentration.
Data are ﬁtted to smooth curves, and from these curves, protein con-
centrations are evaluated at constant polarization, as illustrated below.
Assuming that constant polarization corresponds to constant binding
density, and that constant binding density corresponds to constant free toxin
concentration, then at constant polarization:
Ltot ¼ Lf 1 rPtot; (7)
where Ltot is the total toxin concentration, Lf is the unbound toxin
concentration, Ptot is the total polymer concentration, and r is the binding
density (toxin bound per unit of polymer concentration). From this equation
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we see that a plot of Ltot versus Ptot at constant polarization (constant r) will
give a plot with a slope of the binding density and an intercept of the free
toxin concentration.
Binding analysis
Values of r versus Lf obtained from the ﬂow data and from the isoparametric
analysis are ﬁtted to the model for binding to independent and identical sites:
r ¼
N
Kd
Lf
11
Lf
Kd
: (8)
In this equation we have deﬁned N as the average number of toxin
binding sites on each polymer molecule. Kd is the dissociation binding
constant (on a per site basis), and the other parameters are as deﬁned above.
Note that the dissociation constant on a per molecule basis is equal to Kd/N.
N/Kd thus deﬁnes the y-intercept on a Scatchard plot of r/Lf versus r.
RESULTS
Pulsed ultraﬁltration
To assess the net electrostatic contribution to the binding free
energy, binding measurements were performed at two
different salt concentrations. Fig. 1, a and b, show the PUF
curves for toxin A binding to tolevamer in low salt (0.05 M
Na1) and physiological salt (0.15 M Na1) phosphate buffer,
respectively. It can be discerned from Fig. 1 a that the area
under the curve in the presence of polymer is less than the
area in the absence of polymer, and hence that the binding
of toxin A under these low salt conditions is irreversible.
A quantitative comparison of the areas shows that toxin A
leaving the cell is reduced by 28% when tolevamer is present
in the cell. The amount of toxin A that remains in the cell
under these low salt conditions corresponds to ;2.5 toxin A
molecules bound per every polymer molecule. In contrast,
a quantitative comparison of the curves in Fig. 1 b shows that
the areas are equal to within 2%. Hence, under physiological
salt conditions, binding is reversible. Qualitatively, it can be
seen from a comparison of Fig. 1, c and d, that the binding
of toxin B to tolevamer is stronger at low salt than at
physiological salt. A quantitative discussion of this point will
be presented below.
For comparison, we examined the binding of toxins A and
B to another high molecular mass sulfonated polyanion,
AMPS. Fig. 2 demonstrates that AMPS has no effect on the
ﬂow behavior of either toxins A or B, even under low salt
conditions. Hence, the binding of AMPS to these toxins is
too weak to measure under the conditions of our experi-
ments.
Binding curves extracted from the data of Fig. 1 are shown
in Fig. 3 for toxins A and B, at 0.15 M Na1, and for toxin B
at 0.05 M Na1. These data are plotted as r versus Lf. For the
data taken at 0.15 M Na1, the low range of binding densities
covered does not allow us to obtain an estimate of the N, the
total number of toxin binding sites on each polymer. From
a linear ﬁt of the data we obtain Kd/N ¼ 133 nM and 8.7 mM
for toxins A and B, respectively. From the data for toxin B at
0.05 M Na1, shown in Fig. 3 c, we are able to ﬁt the data to
Eq. 8, and from this ﬁtting we obtain Kd/N ¼ 120.9 6 0.4
nM, and N¼ 0.2036 0.0004. The small N obtained for toxin
B at 0.05 M NaCl is notable, and suggests that under these
low salt conditions a single molecule of toxin B can bind;5
molecules of polymeric drug.
If a net number m of sodium ions are released during the
binding process, then the observed association constants will
increase according to Anderson and Record (1990)
DlogKd
DlogNa
1 ¼ m: (9)
FIGURE 1 Flow proﬁles for toxins A and B at two salt concentrations. (a)
0.04 mg toxin A, and 0.015 mg tolevamer, in 0.05 M phosphate buffer. (b)
0.02 mg toxin A and 0.03 mg tolevamer, in 0.15 M phosphate buffer. (c)
0.031 mg toxin B and 0.06 mg tolevamer in 0.05 M phosphate buffer, and
(d) 0.0176 mg toxin B and 1.0 mg tolevamer in 0.15 M phosphate buffer. In
all cases, the dotted curve is for the toxin in the absence of polymeric drug,
whereas the solid curve is for the toxin in the presence of the indicated
amount of tolevamer.
FIGURE 2 Flow proﬁles for toxins A and B in the presence of AMPS, in
0.05 M phosphate buffer. (a) 0.02 mg toxin A, and 0.03 mg AMPS. (b)
0.044 mg toxin B and 0.06 mg AMPS. In both cases, the dotted curve is for
the toxin in the absence of AMPS, whereas the solid curve is for the toxin in
the presence of the indicated amount of AMPS.
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Using this equation, and equilibrium constants determined
at 0.05 M Na1 and at 0.15 M Na1, we estimate that m ¼ 3.9
sodium ions are released during the association process for
toxin B. This small net number of sodium ions released
suggests that ionic interactions do not dominate the binding
free energy.
Fluorescence polarization
Polarization data for toxin A binding to FL-tolevamer are
shown in Fig. 4 a. The relatively low polarization values that
are observed for tolevamer are not surprising, and reﬂect the
high internal ﬂexibility of this linear chain molecule. By
curve-ﬁtting the data we can obtain plots of Ltot versus Ptot at
constant polarization, as shown in Fig. 4 b. In obtaining these
plots, we used polarization values over the range of 150–160
mP. By using this polarization range we were able to use
well-deﬁned values of Ltot at each value of Ptot. Linear ﬁts of
Ltot versus Ptot allowed us to determine Lf and r from the
intercepts and slopes, respectively. These values of Lf and r
are plotted in Fig. 5, and ﬁtted to Eq. 8 to give Kd/N¼ 366 4
nM, and N ¼ 3.6 6 0.2 for the binding of toxin A to
Fl-tolevamer at 0.15 M Na1.
DISCUSSION
Binding of toxins A and B provides a quantitative
explanation of the biological activity of tolevamer
Under conditions of a large excess of polymer over toxin, as
are anticipated for patients under treatment with this
polymer, the free concentration of polymer should nearly
equal the total concentration of polymer, and the fraction fb
of bound toxin will be given by
fb ¼
N
Kd
Ptot
11
N
Kd
Ptot
; (10)
where Ptot is the total concentration of polymer. Note that fb
does not depend on the total concentration of toxin, provided
that the polymer concentration is in excess.
FIGURE 3 Binding curves extracted from the data of Fig. 1, plotted as r
versus Lf. (a) Binding curve for 0.02 mg toxin A, and 0.03 mg tolevamer, in
0.15 PBS. The solid curve is a ﬁtting of the data to a single site binding
model with Kd ¼ 133 nM. (b) Binding curve for 0.0176 mg toxin B, and
1.0 mg tolevamer, in 0.15 PBS. The solid curve is a ﬁtting of the data to a sin-
gle site binding model with Kd ¼ 8.7 mM. (c) Binding curve for 0.031 mg
toxin B, and 0.06 mg tolevamer, in 0.05 PBS. The solid curve is a ﬁtting of
the data to Eq. 8 with Kd/N ¼ 121 6 0.4 nM, and N ¼ 0.203 6 0.0004.
FIGURE 4 (a) Raw polarization data as a function of toxin A
concentration determined at different drug concentrations. On going from
the upper to the lower curve, the concentration of FL-tolevamer is equal to
344 nM (,), 34.4 nM (;), 3.44 nM(s) and 0.34 nM (d), on a per molecule
basis, assuming a polymer molecular mass of 600 kDa. (b) Derived data of
the total toxin concentration versus total concentration of tolevamer, at
constant polarization. The lines represent best least squares linear ﬁts to
constant polarizations of 150 mP (d), 152 mP (s), 154 mP (;), 156 mP
(,), 158 mP (n) and 160 mP (h).
FIGURE 5 Binding curve derived from isoparametric analysis of
ﬂuorescence binding data for tolevamer binding to toxin A over the range
of 150–160 mP. The solid line is a best ﬁt to a single site model with Kd/N¼
36 6 4 nM, and N ¼ 3.6 6 0.2.
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Using Eq. 10 as a starting point, we suggest that the bind-
ing parameters that we have determined provide a quantitative
explanation for the effect of tolevamer on toxin-mediated
inhibition of protein synthesis (Kurtz et al., 2001). In previous
work with Vero cell monolayers we have shown that, at
a concentration of 5 mg/ml, tolevamer completely abolished
the inhibition of protein synthesis by 5 ng/ml toxin A (Kurtz
et al., 2001). Note ﬁrst that 5 ng/ml corresponds to a toxin A
concentration of 17 pM. 5 mg/ml tolevamer gives a polymer
concentration of 8.3 mM. Hence, under the conditions of
these experiments, the polymer is in substantial excess over
the toxin, and Eq. 10 applies. If we substitute the value of Kd/
N¼ 133 nM for toxin A that we have obtained from the PUF
experiment, we determine fb ¼ 0.984. Therefore, 98% of all
toxin A should be bound by tolevamer under the conditions of
these experiments. Hence, under the conditions of these
experiments, the free concentration of toxin A should be
0.016 (5 ng/ml) ¼ 0.08 ng/ml, which, according to the curve
shown in Fig. 1 A of Kurtz et al. (2001), is well below the
threshold for observable biological response.
Kurtz et al. (2001), previously reported that toxin B
completely inhibited protein synthesis in Vero cell mono-
layers at a concentration of 1.25 ng/ml. In contrast, in the
presence of 5 mg/ml polymer, it required 5 ng/ml of toxin B
to completely inhibit protein synthesis. Substituting Kd/N ¼
8.7 mM, we calculate that;50% of all toxin B present under
these conditions should be free. Hence, at 5 ng/ml toxin B, in
the presence of 5 mg/ml polymer, the free toxin concentra-
tion should be 2.5 ng/ml. From the results reported by Kurtz
et al. (2001), 2.5 ng/ml of free toxin B should completely
inhibit protein synthesis. Hence, the binding data agree with
the protein synthesis inhibition data in that the polymer
diminishes, but does not eliminate the effect of toxin B over
the concentration ranges tested in these studies (Kurtz et al,
2001). Our ﬁndings suggest that tolevamer may exert
somewhat greater activity on the inhibition of protein
synthesis than would be anticipated based on the binding
data, although the modest discrepancy is perhaps not re-
markable given the very different experimental parameters.
The ability of tolevamer to neutralize the enterotoxic
activity of Toxin A in a rat ileal loop assay (Kurtz et al., 2001)
is likewise in quantitative agreement with the binding results
reported here. In the ileal loop assay, tolevamer was mixed
with toxin A and injected into rat ileal loops. Fluid
accumulation and permeability were monitored over a 4-h
time period. In these experiments, a dose of 5 mg of
tolevamer abolished both the excess ﬂuid accumulation and
the increase in intestinal permeability that were mediated by
5 mg of toxin A. Since the average volume of a rat ileal loop
is ;0.5–1 ml, the concentration of tolevamer in these ex-
periments was between 5–10 mg/ml. Under these conditions,
the PUF binding analysis would predict that the fraction of
bound toxin should vary from 98.5% to 99.2%.
The binding data reported here provide a reasonable
physical chemical model to support our optimism that
tolevamer may ultimately prove effective as a drug for the
treatment of antibiotic-associated diarrhea. Based on clinical
titers, toxin A in the stool of patients with C. difﬁcile-
associated diarrhea has been estimated as generally ,1 mg/
ml (McFarland et al., 1991). If the volume of liquid in the
patient’s gut is estimated at ;1 L, then the concentration of
polymer should be ;5 mg/ml. If we take the polymer
molecular mass as 600 kDa, and the toxin molecular mass as
300 kDa, then we can calculate the effective concentration of
polymer in the gut to be 8.3 mM (assuming a theoretical dose
of 5 g/day), and the concentration of toxin A to be,3.3 nM.
The large excess of polymer over toxin assures Eq. 10
applies. Under these conditions, as per our previous calcula-
tions, 98% of all toxin A in the gut should be bound. For
5 mg/ml tolevamer, as per our previous calculations, we can
estimate that ;50% of all toxin B present in the gut should
be bound. We note however, that our calculations do not take
into account the unknown effect of other gut contents on the
binding of toxins A and B to tolevamer.
The correlations that we ﬁnd between binding and bio-
logical activity for tolevamer contrast sharply with our ﬁnd-
ings for the control polyanion AMPS. AMPS has been tested
alongside tolevamer and has failed to demonstrate C. difﬁcile
toxin A or toxin B neutralization in cellular models of toxin
activity (unpublished data and Kurtz et al., 2001). In the
hamster model of C. difﬁcile colitis, AMPS also showed no
measurable activity in preventing toxin-mediated colitis and
mortality. Both of these observations are consistent with the
inability of AMPS to bind toxins A or B in either of our
binding assays.
The binding of tolevamer to C. difﬁcile toxins is
not purely electrostatic in origin
Only four sodium ions are thermodynamically released upon
binding of toxin B to tolevamer. This small number of
sodium ions suggests that the nonspeciﬁc, electrostatic inter-
action between tolevamer and the toxins, although signiﬁ-
cant at lower salt concentrations, does not dominate the
binding thermodynamics under physiological conditions.
FIGURE 6 A schematic illustration of how multiple contacts stabilize the
interaction of individual toxin molecules with a linear polymer of tolevamer.
Based on our calculations, 800 monomer units of tolevamer, or a linear
stretch of 1400 A˚, bind one molecule of toxin A. Since there are ;3,000
monomer units for a polymer of an average molecular mass of 600 kDa, this
implies that, as illustrated, each polymer molecule can bind, on average, 3–4
toxin molecules.
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This conclusion is further supported by the observation that
neither toxin A nor toxin B binds to any measurable extent to
AMPS, despite the fact that the overall charge density on this
polyanion is comparable to that on tolevamer. This dif-
ference between AMPS and tolevamer cannot be explained
by the higher molecular mass of the tolevamer sample (600
kDa) compared to the AMPS sample (200 kDa), since based
on our ﬂuorescence polarization results, the AMPS sample
should be long enough to contain at least one strong toxin-
binding site.
Multiple contacts stabilize the
polymer-toxin interaction
The data that we have obtained at higher binding densities
suggests that tolevamer interacts with toxins A and B
throughmultiple weak contacts. Thus, analysis of the ﬂuores-
cence polarization data for the binding of FL-tolevamer to
toxin A suggests that a single 600 kDa polymer can bind
;3–4 toxin molecules. Since the monomer molecular mass
of the polymer is 206 Da, this implies that a single toxin
molecule interacts with ;800 monomer units on the
polymer. The extended length of an individual monomer is
;1.8 A˚, implying that a single toxin molecule interacts with
a linear region of the polymer of ;1400 A˚. Assuming
a roughly spherical shape and a speciﬁc volume of 0.7 cm3/g
(van Holde, 1985), for a protein of molecular mass 300 kDa,
we can estimate a radius of ;44 A˚, and a circumference of
;300 A˚. As illustrated in the cartoon shown in Fig. 6, if such
a toxin were to interact with an extended length of a polymer
in the range of 1000–2000 A˚, the polymer would need to
wrap around the toxin on average ;4–5 times, and could
bind a maximum of;3–4 toxin molecules. Though we were
unable to determine N for the interaction of toxin B with
tolevamer at 0.15 M Na1, the binding curves shown in Fig.
3 c indicate that, at least under low salt conditions, toxin B
also interacts with a large number of individual monomer
units on tolevamer.
We hypothesize that the interaction of C. difﬁcile toxins
with such large stretches of tolevamer is likely to seriously
impair the ability of these toxins to recognize and bind to cell
surfaces. The binding of tolevamer may also exert its effects
by inhibiting endocytosis of toxins into the cytoplasm, or by
interfering with the glucosyltransferase activity of RhoA and
related GTPases. As intriguing as these hypotheses are,
resolving the biological effects of tolevamer binding is be-
yond the scope of the current investigation.
The authors thank Professors C. Woodbury and D. Stimson for helpful
discussions, and for help with the design of the pulsed ultraﬁltration cell.
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